EDISON EQUITY RESEARCH: BELLUS HEALTH - AA AMYLOIDOSIS PIVOTAL STUDY FULLY ENROLLED Bellus’s lead candidate, Kiacta, recently reached full recruitment for the pivotal Phase III trial for AA...
Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX:BLU), a drug development company...
- Auven Therapeutics and BELLUS Health Amend the KIACTA™ Asset Purchase and Licensing Agreement - Auven Therapeutics, the global private equity company focused on accelerated development...
Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and Bellus Health Inc. (TSX: BLU), a drug development company...
In preparation for its reorganization into Westcore Blue Chip Fund, the Directors of Blue Chip Value Fund, Inc. (NYSE: BLU) announced that the last day of trading in Blue Chip...
Blue Chip Value Fund, Inc. (NYSE:BLU) announced today that its stockholders have approved the reorganization of the Fund into Westcore Blue Chip Fund, a series of Westcore...
Blue Chip Value Fund (NYSE: BLU), today, announced that the $0.0178 annual dividend, payable January 14, 2011, for 2010 was from net investment income. Further, 100% qualifies...
The Directors of Blue Chip Value Fund, Inc. (NYSE: BLU) have declared a distribution of $0.0178 per share. This distribution is payable January 14, 2011, to stockholders of...
Blue Chip Value Fund, Inc. (NYSE:BLU) and Westcore Blue Chip Fund (WTMVX) announced today that their respective Boards of Directors and Trustees have formally approved the plan...
Blue Chip Value Fund, Inc. (NYSE:BLU) and Westcore Blue Chip Fund (WTMVX) announced today that their respective Boards of Directors and Trustees have given preliminary approval...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |